- Home
- KORE vs VYNE Comparison
KORE vs VYNE Comparison
Compare KORE & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KORE
- VYNE
- Stock Information
- Founded
- KORE 2003
- VYNE 2003
- Country
- KORE United States
- VYNE United States
- Employees
- KORE N/A
- VYNE N/A
- Industry
- KORE Telecommunications Equipment
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- KORE Consumer Discretionary
- VYNE Health Care
- Exchange
- KORE Nasdaq
- VYNE Nasdaq
- Market Cap
- KORE 39.6M
- VYNE 35.7M
- IPO Year
- KORE N/A
- VYNE 2018
- Fundamental
- Price
- KORE $2.75
- VYNE $0.93
- Analyst Decision
- KORE Hold
- VYNE Strong Buy
- Analyst Count
- KORE 2
- VYNE 2
- Target Price
- KORE $2.75
- VYNE $6.25
- AVG Volume (30 Days)
- KORE 11.1K
- VYNE 259.3K
- Earning Date
- KORE 05-15-2025
- VYNE 05-08-2025
- Dividend Yield
- KORE N/A
- VYNE N/A
- EPS Growth
- KORE N/A
- VYNE N/A
- EPS
- KORE N/A
- VYNE N/A
- Revenue
- KORE $282,254,000.00
- VYNE $605,000.00
- Revenue This Year
- KORE $4.53
- VYNE N/A
- Revenue Next Year
- KORE $6.86
- VYNE N/A
- P/E Ratio
- KORE N/A
- VYNE N/A
- Revenue Growth
- KORE N/A
- VYNE 43.03
- 52 Week Low
- KORE $1.10
- VYNE $0.95
- 52 Week High
- KORE $4.88
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- KORE 56.67
- VYNE 25.37
- Support Level
- KORE $2.33
- VYNE $0.96
- Resistance Level
- KORE $2.57
- VYNE $1.09
- Average True Range (ATR)
- KORE 0.14
- VYNE 0.08
- MACD
- KORE 0.03
- VYNE -0.01
- Stochastic Oscillator
- KORE 86.79
- VYNE 3.42
About KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.